Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
about
Micronutrients in Oncological InterventionMechanism of Platinum Derivatives Induced Kidney InjuryQuantitative structure activity relationship for inhibition of human organic cation/carnitine transporter.Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models.L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trialCisplatin-induced downregulation of OCTN2 affects carnitine wastingUptake carriers and oncology drug safety.Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature.Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.A Potential Biomarker for Acute Kidney Injury in Preterm Infants from Metabolic ProfilingCarnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.Increased urinary excretion of carnitine and acylcarnitine by mercuric chloride is reversed by 2,3-dimercapto-1-propanesulfonic acid in rats.Cisplatin-induced metabolome changes in serum: an experimental approach to identify markers for ototoxicity.Repeated Combined Chemotherapy with Cisplatin Lowers Carnitine Levels in Gastric Cancer Patients.
P2860
Q26764839-9AA4F468-A140-4137-A1AE-836678430BDAQ26783436-0DF93A5C-D4EB-4ABB-B890-54B11E7A039DQ34384867-FF45A806-FCCF-4085-B3A3-E7619EC291E8Q35740234-A15B47B0-15D5-4484-AB6C-088BF2E9C962Q36014607-46DC532A-F9EB-45A4-9706-F2C24ED3AA51Q36226621-CC6E24C1-DB8E-4DD1-A2E5-D0885E4EBA89Q36491674-C03A156E-1E8D-45B9-A075-B03F25F2AE01Q37663396-317ACA6E-BF10-4FC3-BF38-9B8CEF3AC7C3Q38105163-6323A0EF-3971-4080-9797-7A224C957355Q38130229-AE2A3561-2284-4914-9F68-0C230A5F2F9CQ42228034-CFEDEC69-0B42-4328-A6A7-E70A039942A9Q42412090-0ACE3658-EDEA-428E-BF44-F79386828E7EQ43071427-00F02711-BABA-48EC-B1B8-FFD8E0710D8EQ46891118-D341164A-A40A-46A5-86B8-3921290F90CEQ47297270-448981D9-07A4-4A31-9DC8-E3C1D0C5EFEE
P2860
Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@en
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@nl
type
label
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@en
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@nl
prefLabel
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@en
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@nl
P2093
P356
P1476
Urinary excretion of carnitine ...... in-based antineoplastic drugs.
@en
P2093
Katerina Novakova
Liliane Todesco
Manuel Haschke
Richard Herrmann
Saskia Lüde
Stephan Krähenbühl
Tanja Vitins
P304
P356
10.1093/NDT/GFP456
P407
P577
2009-09-07T00:00:00Z